CPT code 0332U: Immunotherapy response profile, eight epigenetic markers2026 Medicare lab fee · Clinical Laboratory Fee Schedule
This whole-blood oncology assay profiles eight epigenetic markers by qPCR and reports a high or low probability of response to immune checkpoint-inhibitor therapy.
Medicare pays $1,142.06 for 0332U under the 2026 Clinical Laboratory Fee Schedule: one national amount, the same in every state and setting.
Medicare lab fee · CLFS 2026 Q4
National CLFS amount
$1,142.06
In effect since Jan 1, 2026. The same amount in every state, payment locality and setting.
- Geographic adjustment
- None
- Office vs facility
- Same
- Since 2024
- Unchanged
- CMS updates
- Quarterly
Medicare pays the lesser of the lab’s charge and this amount. Patients usually owe no Part B deductible or coinsurance for covered clinical lab tests.
On this page 7 sections
What 0332U covers
This oncology test analyzes whole blood by quantitative polymerase chain reaction (qPCR), profiling eight DNA-regulatory, or epigenetic, markers. Its reported result places the probability of responding to immune checkpoint-inhibitor therapy in a high or low category. This is a treatment-response probability assessment, not a direct measurement of treatment response. Use this code when the laboratory performs the described eight-marker whole-blood profiling assay and reports its response-probability category.
Medicare pays 0332U under the Clinical Laboratory Fee Schedule (CLFS) at one national amount per code, with no locality, geographic, or office-versus-facility adjustment. The 2026 national CLFS amount is $1,142.06, unchanged from 2024 and 2025. The code is paid through the CLFS only, with no physician fee schedule payment.
This summary was written with AI assistance from CMS Clinical Laboratory Fee Schedule data. Amounts on this page come directly from CMS files.
How Medicare pays 0332U
Clinical lab tests aren’t priced like physician services. They’re paid from their own fee schedule, with its own rules. See the whole lab fee schedule.
One national amount
CMS sets a single Clinical Laboratory Fee Schedule amount for 0332U. There’s no geographic (GPCI) adjustment, so it pays the same in every state and payment locality.
No office or facility rate
Lab tests aren’t built from relative value units, so there’s no office and facility split: the place of service doesn’t change the CLFS amount.
Updated every quarter
CMS republishes the CLFS each quarter. New tests, often proprietary laboratory analyses (PLA codes), join during the year; existing amounts are updated each January.
Not on the physician fee schedule
The physician fee schedule doesn’t list 0332U: Medicare pays the test only from the CLFS.
0332U on the lab fee schedule since 2022
0332U · CLFS 2026 Q4 (current)
$1,142.06
Unchanged since Jan 1, 2024
Every change on file
- Jan 1, 2024 · CLFS 2024 Q1MAC-priced → $1,142.06
17 quarterly CLFS releases on file, first CLFS 2022 Q4. A code missing from a quarter wasn’t on that release.
0332U compared with similar tests
- 0333ULiver cancer surveillancecfDNA and serum-marker algorithm$662.32
- 0333U is an oncology assay for liver cancer surveillance using circulating tumor DNA; 0332U evaluates the probability of response to immune checkpoint-inhibitor therapy.
- 0334UTumor sequencing84 or more genes$3,500.00
- 0334U is a solid-organ tumor genomic assay, whereas 0332U profiles eight epigenetic markers in whole blood to assess likely response to immunotherapy.
- 0339UProstate RNA testHOXC6 and DLX1 expression$760.00
- 0339U evaluates prostate-associated HOXC6 and DLX1 mRNA; 0332U profiles epigenetic markers for an immune checkpoint-inhibitor response assessment.
0332U billing questions
What specimen and method identify this assay?
It uses whole blood and quantitative polymerase chain reaction to profile eight epigenetic markers.
What does the result report?
It reports a high or low probability of responding to immune checkpoint-inhibitor therapy.
How does 0332U differ from 0333U?
0332U assesses probability of response to immune checkpoint-inhibitor therapy; 0333U is an oncology assay for liver cancer surveillance using circulating tumor DNA.
How does 0332U differ from 0334U?
0332U profiles eight epigenetic markers in whole blood for an immune checkpoint-inhibitor response assessment. 0334U is a solid-organ tumor genomic assay.
How does Medicare pay 0332U?
Medicare pays it through the CLFS at one national amount per code, with no locality, geographic, or office-versus-facility adjustment.
Where this amount comes from
FeeBase reads lab amounts directly from the CMS Clinical Laboratory Fee Schedule file for the quarter: one row per code, with its payment indicator and national amount. Contractor-priced tests are labeled, never given a made-up amount. Amounts are Medicare payment limits, not a patient’s bill or a commercial rate.
CMS CLFS 2026 Q4 · effective Oct 1, 2026 through the day before Jan 1, 2027
Show the CMS file line behind this amount
Fee sheets · Coming soon
Put 0332U and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist